Skip to main content
OpenTrials
Completed

NCT Number: NCT01081509

Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence

The aim of this study is to assess the patient's perception about and willingness to take his or her medication and the influencing factors interfering with taking medication.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Observational

Primary location

Research Site, Balatonföldvár, Hungary

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Early breast cancer
  • Post menopausal
  • Adjuvant hormonal Arimidex therapy

Treatment and study plan

Primary outcomes

  1. Percent of patients remaining adherent to therapy with Arimidex

    Time frame: Every 3 months

Secondary outcomes

  1. Questionnaire for factors influencing adherence

    Time frame: Every 3 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Survey and Follow-up of the Treatment Adherence and Medication Habits of Early Breast Cancer Patients on Adjuvant Hormonal Therapy With the Aromatase Inhibitor Arimidex

Acronym: ARIADNE

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Mar 5, 2010
Registry last updated
Nov 16, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.